Results 21 to 30 of about 857,892 (246)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

New England Journal of Medicine, 2021
Background Despite high vaccine coverage and effectiveness, the incidence of symptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been increasing in Israel.
Einav G. Levin, Y. Lustig, Carmit Cohen, R. Fluss, V. Indenbaum, S. Amit, R. Doolman, K. Asraf, E. Mendelson, A. Ziv, Carmit Rubin, L. Freedman, Y. Kreiss, G. Regev-Yochay   +13 more
semanticscholar   +1 more source

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

New England Journal of Medicine, 2020
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine.
L. Jackson, E. Anderson, N. Rouphael, P. Roberts, M. Makhene, R. Coler, M. P. McCullough, J. Chappell, M. Denison, Laura J. Stevens, A. Pruijssers, A. McDermott, B. Flach, N. Doria-Rose, Kizzmekia S. Corbett, Kaitlyn M. Morabito, S. O'dell, S. Schmidt, P. Swanson, M. Padilla, J. Mascola, K. Neuzil, H. Bennett, Wellington Sun, E. Peters, M. Makowski, J. Albert, Kaitlyn A. Cross, Wendy L. Buchanan, Rhonda Pikaart-Tautges, J. Ledgerwood, B. Graham, J. Beigel   +32 more
semanticscholar   +1 more source

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

New England Journal of Medicine, 2020
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide.
E. Walsh, R. Frenck, A. Falsey, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, K. Neuzil, M. Mulligan, R. Bailey, K. Swanson, Ping Li, K. Koury, W. Kalina, David Cooper, Camila R. Fontes-Garfias, P. Shi, Ö. Türeci, Kristin Tompkins, Kirsten E. Lyke, V. Raabe, P. Dormitzer, K. Jansen, U. Şahin, W. Gruber   +24 more
semanticscholar   +1 more source

Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom

Nature Communications, 2021
Identifying and understanding COVID-19 vaccine hesitancy within distinct populations may aid future public health messaging. Using nationally representative data from the general adult populations of Ireland (N = 1041) and the United Kingdom (UK; N ...
Jamie Murphy, F. Vallières, R. Bentall, M. Shevlin, O. McBride, T. Hartman, R. McKay, K. Bennett, L. Mason, J. Gibson-Miller, L. Levita, Antón P. Martínez, T. Stocks, T. Karatzias, P. Hyland   +14 more
semanticscholar   +1 more source

Vaccine adjuvants: mechanisms and platforms

Signal Transduction and Targeted Therapy, 2023
Adjuvants are indispensable components of vaccines. Despite being widely used in vaccines, their action mechanisms are not yet clear. With a greater understanding of the mechanisms by which the innate immune response controls the antigen-specific ...
Tingmei Zhao, Yulong Cai, Yujie Jiang, Xuemei He, Yuquan Wei, Yifan Yu, Xiaohe Tian   +6 more
semanticscholar   +1 more source

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

New England Journal of Medicine, 2021
Background BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine encoding a prefusion-stabilized, membrane-anchored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) full-length spike protein.
Stephen J. Thomas, E. Moreira, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, John L. Perez, Gonzalo Pérez Marc, F. Polack, C. Zerbini, R. Bailey, K. Swanson, Xia Xu, Satrajit Roychoudhury, K. Koury, S. Bouguermouh, W. Kalina, David Cooper, R. Frenck, L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal, Qi Yang, P. Liberator, D. Tresnan, Susan H. Mather, P. Dormitzer, U. Şahin, W. Gruber, K. Jansen   +31 more
semanticscholar   +1 more source

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

New England Journal of Medicine, 2021
Background Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 ...
S. Madhi, V. Baillie, C. Cutland, M. Voysey, A. Koen, L. Fairlie, S. Padayachee, K. Dheda, S. Barnabas, Q. Bhorat, Carmen Briner, G. Kwatra, K. Ahmed, P. Aley, Sutika Bhikha, J. Bhiman, A. Bhorat, J. du Plessis, A. Esmail, M. Groenewald, E. Horne, Shi-Hsia Hwa, A. Jose, T. Lambe, M. Laubscher, M. Malahleha, Masebole Masenya, Mduduzi S. L. Masilela, Shakeel Mckenzie, Kgaogelo Molapo, A. Moultrie, S. Oelofse, Faeezah Patel, S. Pillay, S. Rhead, H. Rodel, Lindie Rossouw, Carol Taoushanis, H. Tegally, Asha Thombrayil, Samuel van Eck, C. K. Wibmer, N. Durham, E. Kelly, T. Villafana, S. Gilbert, A. Pollard, Tulio de Oliveira, P. Moore, A. Sigal, A. Izu   +50 more
semanticscholar   +1 more source

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile

New England Journal of Medicine, 2021
Background Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed to support decision making.
A. Jara, E. Undurraga, Cecilia González, F. Paredes, Tomás Fontecilla, G. Jara, A. Pizarro, Johanna Acevedo, Katherine Leo, Francisco Leon, Carlos Sans, Paulina Leighton, P. Suárez, Heriberto E. García-Escorza, R. Araos   +14 more
semanticscholar   +1 more source

Vaccine hesitancy: the next challenge in the fight against COVID-19

European Journal of Epidemiology, 2020
Vaccine hesitancy remains a barrier to full population inoculation against highly infectious diseases. Coincident with the rapid developments of COVID-19 vaccines globally, concerns about the safety of such a vaccine could contribute to vaccine hesitancy.
A. Dror, N. Eisenbach, S. Taiber, N. Morozov, Matti Mizrachi, Asaf Zigron, S. Srouji, E. Sela   +7 more
semanticscholar   +1 more source

Varicella: to vaccinate or not to vaccinate? [PDF]

Archives of Disease in Childhood, 1998
Editor,—I am in complete agreement with Dr Aebi that strategies for delivering varicella vaccine effectively are critical to the success of immunisation programmes.1 In the USA great efforts are being made in this direction. Nevertheless, despite the licensure of varicella vaccine for routine use in the United …
openaire   +5 more sources